The Journal of Immunology, Vol 141, Issue 1 189-200, Copyright © 1988 by American Association of Immunologists

ARTICLES

Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice

MK Gately, TD Anderson and TJ Hayes
Department of Immunopharmacology, Hoffmann-La Roche, Inc., Nutley, NJ 07110.

Studies were performed to characterize the toxic effects of human rIL-2 in mice and to examine the mechanism of toxicity. Intraperitoneal administration of rIL-2 at doses greater than or equal to 2 X 10(6) U/kg twice each day for greater than or equal to 4 days led to toxicity in several strains of mice. The toxic effects of rIL-2 included the vascular leak syndrome (manifested by pulmonary edema, pleural effusions, and ascites), elevated hepatic transaminases, hyperbilirubinemia, hypoalbuminemia, pre-renal azotemia, anemia, thrombocytopenia, mild eosinophilia, and death. Marked lymphoid cell infiltration of pulmonary and hepatic vasculature was present in mice suffering from rIL-2 toxicity, and the pleural and ascitic fluids also contained high numbers of mononuclear cells. Mononuclear cells isolated from the pleural fluids and livers of these mice were 74 to 98% Thy-1+, 55 to 83% asialo-GM1+, 29 to 45% Lyt-2+, and less than 10% L3T4+. These cells possessed potent lymphokine-activated killer (LAK)-like activity in that their ability to lyse cells of the NK-resistant P815 mastocytoma line was 10- to 100-fold higher on a per cell basis than splenocytes from the same animals. A correlation was found between the dose level, duration, and frequency of dosing with rIL-2 required to induce pleural effusions and hepatotoxicity and the dosage regimens required to produce the LAK-like cells in the pleural cavities and livers, respectively, of rIL-2-treated mice. Moreover, treatment of mice with anti-asialo-GM1 (anti-ASGM-1) antiserum in vivo at the same time they were receiving toxic doses of rIL-2 abolished or greatly reduced the severity of the vascular leak syndrome and hepatotoxicity and significantly prolonged the survival of the mice. Administration of anti-ASGM-1 to mice receiving toxic doses of rIL-2 resulted in a marked reduction in the LAK-like cytolytic activity of their pleural and liver lymphoid cells and a corresponding reduction in the percentage of ASGM- 1+ cells in pulmonary and hepatic lymphoid infiltrates. Nevertheless, the overall extent of pulmonary and hepatic lymphoid infiltration, as well as other consequences of rIL-2 administration, including splenomegaly, hypoalbuminemia, eosinophilia, and thrombocytopenia, were not diminished as a result of anti-ASGM-1 treatment.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				M. M. W. Chong, D. Metcalf, E. Jamieson, W. S. Alexander, and T. W. H. Kay Suppressor of cytokine signaling-1 in T cells and macrophages is critical for preventing lethal inflammation Blood, September 1, 2005; 106(5): 1668 - 1675. [Abstract] [Full Text] [PDF]

				E. Assier, V. Jullien, J. Lefort, J.-L. Moreau, J. P. Di Santo, B. B. Vargaftig, J. R. Lapa e Silva, and J. Theze NK Cells and Polymorphonuclear Neutrophils Are Both Critical for IL-2-Induced Pulmonary Vascular Leak Syndrome J. Immunol., June 15, 2004; 172(12): 7661 - 7668. [Abstract] [Full Text] [PDF]

				A. L. Cornish, M. M. Chong, G. M. Davey, R. Darwiche, N. A. Nicola, D. J. Hilton, T. W. Kay, R. Starr, and W. S. Alexander Suppressor of Cytokine Signaling-1 Regulates Signaling in Response to Interleukin-2 and Other {gamma}c-dependent Cytokines in Peripheral T Cells J. Biol. Chem., June 13, 2003; 278(25): 22755 - 22761. [Abstract] [Full Text] [PDF]

				M. Okamoto, S. Kato, K. Oizumi, M. Kinoshita, Y. Inoue, K. Hoshino, S. Akira, A. N. J. Mckenzie, H. A. Young, and T. Hoshino Interleukin 18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia Blood, February 15, 2002; 99(4): 1289 - 1298. [Abstract] [Full Text] [PDF]

				C.-y. Wu, X. Wang, M. Gadina, J. J. O'Shea, D. H. Presky, and J. Magram IL-12 Receptor {beta}2 (IL-12R{beta}2)-Deficient Mice Are Defective in IL-12-Mediated Signaling Despite the Presence of High Affinity IL-12 Binding Sites J. Immunol., December 1, 2000; 165(11): 6221 - 6228. [Abstract] [Full Text] [PDF]

				G. C. de Gast, H.-J. Klümpen, F. A. Vyth-Dreese, M.-J. Kersten, N. C. V. Verra, J. Sein, D. Batchelor, W. J. Nooijen, and J. H. Schornagel Phase I Trial of Combined Immunotherapy with Subcutaneous Granulocyte Macrophage Colony-stimulating Factor, Low-Dose Interleukin 2, and Interferon {{alpha}} in Progressive Metastatic Melanoma and Renal Cell Carcinoma Clin. Cancer Res., April 1, 2000; 6(4): 1267 - 1272. [Abstract] [Full Text]